Leerink Partnrs Predicts Stronger Earnings for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at Leerink Partnrs boosted their FY2026 earnings estimates for shares of REGENXBIO in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of $0.28 for the year, up from their prior forecast of ($0.52). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.85) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2027 earnings at ($0.14) EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.21 EPS.

Several other research firms have also recently commented on RGNX. StockNews.com cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. Raymond James reaffirmed an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a research report on Wednesday, January 15th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.82.

REGENXBIO Stock Up 7.8 %

Shares of REGENXBIO stock opened at $8.43 on Monday. The firm has a market cap of $417.62 million, a PE ratio of -1.68 and a beta of 1.29. REGENXBIO has a 12-month low of $6.56 and a 12-month high of $28.80. The company’s fifty day simple moving average is $8.18 and its two-hundred day simple moving average is $10.13.

Institutional Trading of REGENXBIO

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd bought a new stake in REGENXBIO during the 4th quarter valued at about $1,062,000. Hennion & Walsh Asset Management Inc. increased its stake in REGENXBIO by 8.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 13,014 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after acquiring an additional 296,700 shares during the period. GAMMA Investing LLC grew its stake in shares of REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares during the period. Finally, Barclays PLC grew its stake in shares of REGENXBIO by 141.3% in the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock worth $1,217,000 after acquiring an additional 67,948 shares during the period. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.